GWENDOLYN ORFAN: Open Payments
NPI 1538538871 · HAGERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$689 in 35 payments from 12 companies in 2025. Trend: 2023 $115 · 2024 $829 · 2025 $689
Food & beverage: $689
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 9 | $141 |
| Lilly USA, LLC | 9 | $136 |
| Medtronic, Inc. | 3 | $97 |
| Novo Nordisk Inc | 4 | $81 |
| SANOFI-AVENTIS U.S. LLC | 3 | $63 |
| Madrigal Pharmaceuticals | 1 | $31 |
| Insulet Corporation | 1 | $28 |
| Corcept Therapeutics | 1 | $25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
Products named: FREESTYLE LIBRE 3, MOUNJARO, MINIMED 780G, Ozempic, TZIELD, REZDIFFRA, Omnipod, Korlym.
Industry payments across MD — which companies pay providers there.
